Literature DB >> 8413947

Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies.

A Chiba1, S Kusunoki, H Obata, R Machinami, I Kanazawa.   

Abstract

To determine the significance of serum anti-GQ1b IgG antibody, we studied the disease spectrum associated with this antibody and GQ1b epitope in the human nervous system. We examined sera from 19 patients with typical Miller Fisher syndrome (MFS), five patients with acute postinfectious ophthalmoplegia without ataxia (atypical MFS), six patients with Guillain-Barré syndrome (GBS) with ophthalmoplegia (GBS-OP[+]), and 23 patients with GBS without ophthalmoplegia (GBS-OP[-]). We also examined sera from 84 patients with other neurologic or non-neurologic disorders and from 16 normal control subjects. Eighteen of the 19 patients with typical MFS, all the patients with atypical MFS, and five of the six patients with GBS-OP(+) had increased anti-GQ1b IgG activity in ELISA, but none of the patients in the other groups, including GBS-OP(-), had it. All the patients' sera that had anti-GQ1b IgG antibody showed anti-GT1a IgG activity. Results of absorption studies suggested that the same antibody reacted with GQ1b and GT1a. An anti-GQ1b mouse monoclonal antibody immunostained the paranodal regions of the extramedullary portion of the human oculomotor, trochlear, and abducens nerves. Biochemical analysis showed that the human oculomotor nerve contained a larger amount of GQ1b than did the ventral and dorsal roots of the spinal cord. We conclude that serum IgG antibody against GQ1b is very closely associated with acute postinfectious ophthalmoplegia in MFS and GBS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413947     DOI: 10.1212/wnl.43.10.1911

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  105 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  Specificity of antiglycolipid antibodies.

Authors:  N Baumann
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 3.  Guillain Barré syndrome.

Authors:  J B Winer
Journal:  Mol Pathol       Date:  2001-12

4.  Bickerstaff's encephalitis and the Miller Fisher syndrome.

Authors:  J B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

5.  Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection.

Authors:  B Schwerer; A Neisser; H Bernheimer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Fisher syndrome.

Authors:  Masahiro Mori; Satoshi Kuwabara
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

7.  Isolated abducens nerve paresis associated with high titer of anti-asialo-GM1 following Campylobacter jejuni enteritis.

Authors:  Juri Katchanov; Jan Dirks Lünemann; Florian Masuhr; Andreas Meisel; Helgard Möller; Rolf Zschenderlein
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

8.  The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome.

Authors:  Peggy C R Godschalk; Astrid P Heikema; Michel Gilbert; Tomoko Komagamine; C Wim Ang; Jobine Glerum; Denis Brochu; Jianjun Li; Nobuhiro Yuki; Bart C Jacobs; Alex van Belkum; Hubert P Endtz
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function.

Authors:  Roland W M Bullens; Graham M O'Hanlon; Eric Wagner; Peter C Molenaar; Keiko Furukawa; Koichi Furukawa; Jaap J Plomp; Hugh J Willison
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

10.  Anti-GQ1b ganglioside antibody and ophthalmoplegia of undetermined cause.

Authors:  T Suzuki; A Chiba; S Kusunoki; M Chikuda; T Fujita; K Misu
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.